Cost-effectiveness analysis of rivaroxaban for treatment and secondary prevention of venous thromboembolism in the Netherlands-Reference-Cited by-同舟云学术

Cost-effectiveness analysis of rivaroxaban for treatment and secondary prevention of venous thromboembolism in the Netherlands

Published:2017-06-25 Issue:8 Volume:20 Page:813-824
ISSN:1369-6998
Container-title:Journal of Medical Economics
language:en
Short-container-title:Journal of Medical Economics

Author:

Heisen Marieke¹^ORCID,Treur Maarten J.¹,Heemstra Harald E.²,Giesen Eric B. W.³,Postma Maarten J.⁴⁵⁶

Affiliation:

1. Pharmerit International, Rotterdam, The Netherlands;

2. Bayer B.V., Mijdrecht, The Netherlands;

3. Bayer Pharma AG, Berlin, Germany;

4. Unit of PharmacoEpidemiology & PharmacoEconomics (PE2), Department of Pharmacy, University of Groningen, Groningen, The Netherlands;

5. Department of Epidemiology, University Medical Center Groningen (UMCG), University of Groningen, Groningen, The Netherlands;

6. Institute of Science in Healthy Aging & healthcaRE (SHARE), UMCG, University of Groningen, Groningen, The Netherlands

Publisher

Informa UK Limited

Subject

Health Policy

Link

https://www.tandfonline.com/doi/pdf/10.1080/13696998.2017.1331912

Reference80 articles.

1. 2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism

2. The Epidemiology of Venous Thromboembolism in the Community

3. Venous thromboembolism (VTE) in Europe

4. Lambooij MS, Drewes HW. Risico's en gebrekkige afstemming in de trombosezorg. Rijksinstituut voor Volksgezondheid en Milieu 2010, Bilthoven, the Netherlands

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cost-Effectiveness Analysis of MammaPrint® to Guide the Use of Endocrine Therapy in Patients with Early-Stage Breast Cancer;PharmacoEconomics;2023-05-28

2. Economic Evaluation of Direct Oral Anticoagulants Compared to Warfarin for Venous Thromboembolism in Thailand: A Cost-Utility Analysis;International Journal of Environmental Research and Public Health;2023-02-11

3. Cost‐of‐Illness Analysis of Long‐Term Health Care Resource Use and Disease Burden in Patients With Pulmonary Embolism: Insights From the PREFER in VTE Registry;Journal of the American Heart Association;2022-10-18

4. Cost-Effectiveness of Aspirin for Extended Venous Thromboembolism Prophylaxis After Major Surgery for Inflammatory Bowel Disease;Journal of Gastrointestinal Surgery;2022-03-11

5. Do Cost Limitations of Extended Prophylaxis After Surgery Apply to Ulcerative Colitis Patients?;Diseases of the Colon & Rectum;2021-11-22